Endophthalmitis After Dexamethasone Implant
Clinical & Experimental Ophthalmology · 2026
DOI: 10.1111/ceo.70066 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical & Experimental Ophthalmology, 2026. Verfasst von Maryam Eghtedari und 4 weiteren Autor:innen. Beteiligte Einrichtung: Vitreo-Retinal Unit, Royal Victorian Eye and Ear Hospital, East Melbourne, Victoria, Australia. Hauptthemen laut MEDLINE: Dexamethasone, Endophthalmitis, Glucocorticoids, Eye Infections, Bacterial. Die Arbeit nennt 47 Literaturangaben.
Abstract (Originalsprache)
Background
The dexamethasone intravitreal implant is used to treat sight‐threatening retinal disorders. Endophthalmitis is a serious complication of intravitreal injections and requires urgent intervention. Recent evidence demonstrates that the dexamethasone implant has higher endophthalmitis rates than some intravitreal injections. We present a large, prospective, state‐wide analysis.
Methods
The Victorian Endophthalmitis Registry prospectively identified all dexamethasone implant‐related endophthalmitis cases from January 2018 to June 2024 in Victoria, Australia, managed at the Royal Victorian Eye and Ear Hospital, a state‐wide service. The Pharmaceutical Benefits Schedule Item Reports available on the Medicare Australia database were used to determine the number of dexamethasone implants in Victoria, Australia, to calculate the incidence rate of dexamethasone implant‐related endophthalmitis.
Results
Fifteen incidences from 9457 implants resulted in endophthalmitis (rate = 0.16%, 1 in 630 injections). All cases received inpatient care with an aqueous and vitreous tap, intravitreal vancomycin, and ceftazidime. Fourteen cases (93%, n = 15) underwent surgical intervention, including 13 cases of vitrectomy (87%, n = 15). A causative pathogen was isolated in 86.7% of vitreous samples ( n = 13/15), with Staphylococcus epidermidis being the most common, found in seven eyes (46.7%, n = 15). Three eyes (20%, n = 15) underwent enucleation. The remaining 12 eyes had a mean follow‐up visual acuity of Snellen 6/27 (logMAR 0.65 ± 0.43).
Conclusions
The rate of dexamethasone implant‐related endophthalmitis is 0.16% which is higher than other intravitreal injections reported in the literature, with considerably poor visual outcomes. The vitreous diagnostic samples are culture‐positive in 87% of cases (13/15), with 46.7% (7/15) isolating Staphylococcus epidermidis .
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Vitreo-Retinal Unit, Royal Victorian Eye and Ear Hospital, East Melbourne, Victoria, Australia.
- Vitreo-Retinal Unit, St Helens Hospital, St Helens, UK.
- Centre for Eye Research Australia, Melbourne, Victoria, Australia.
- The University of Melbourne, Melbourne, Victoria, Australia.
ORCID-Profile: Maryam Eghtedari, Fatemeh Shams, Rosie C H Dawkins
Zitieren
APA
Eghtedari, M., Chiu, Z., Shams, F., Allen, P. J., & Dawkins, R. C. H. (2026). Endophthalmitis After Dexamethasone Implant. Clinical & Experimental Ophthalmology. https://doi.org/10.1111/ceo.70066
Vancouver
Eghtedari M, Chiu Z, Shams F, Allen PJ, Dawkins RCH. Endophthalmitis After Dexamethasone Implant. Clinical & Experimental Ophthalmology. 2026. doi:10.1111/ceo.70066
BibTeX
@article{Eghtedari2026,
author = {Eghtedari, Maryam and Chiu, Zelia and Shams, Fatemeh and Allen, Penelope J and Dawkins, Rosie C H},
title = {Endophthalmitis After Dexamethasone Implant},
journal = {Clinical & Experimental Ophthalmology},
year = {2026},
doi = {10.1111/ceo.70066}
}
EUVIMED